NCT05968326 — autogene cevumeran (BNT122) neoantigen vaccine trial
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Autogene cevumeran (BNT122 / RO7198457), BioNTech + Genentech/Roche — adjuvant program
Registry record
| Registry ID | NCT05968326 ↗ |
|---|---|
| Lead sponsor | Genentech, Inc. |
| Collaborators | BioNTech SE |
| Phase | Phase 2 |
| Status | Recruiting |
| Indication | Adenocarcinoma, Pancreatic Ductal |
| Enrollment | 260 participants (target) |
| Start date | 2023-10-18 |
| Primary completion | 2031-01-01 (est.) |
| Last registry update | 2 Sept 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT05968326), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT05968326?
NCT05968326 (A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC) is registered on ClinicalTrials.gov as Phase 2, sponsored by Genentech, Inc..
Is NCT05968326 recruiting?
As of the 2026-09-02 registry update, NCT05968326 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT05968326?
The lead sponsor is Genentech, Inc.. Collaborators: BioNTech SE.
What condition does NCT05968326 study?
The registered condition is Adenocarcinoma, Pancreatic Ductal. Primary completion is listed as 2031-01-01 (estimated).
Are results available for NCT05968326?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT05968326.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.